Ototoxicity: A Challenge in Diagnosis and Treatment

키워드

참고문헌 (67)

1. Naunton RF, "The ototoxicity of Kanamycin sulfate in the presence of compromised renal function", AMA Arch Otolaryngol, 69, pp.398~399 (1959)[DOI]
2. Arslan E, "Global problem of drug-induced hearing loss", Ann N Y Acad Sci, 884, pp.1~14 (1999)[DOI]
3. Cianfrone G, "Pharmacological drugs inducing ototoxicity, vestibular symptoms and tinnitus: a reasoned and updated guide", Eur Rev Med Pharmacol Sci, 15, pp.601~636 (2011)
4. Knight KR, "Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development", J Clin Oncol, 23, pp.8588~8596 (2005)[DOI]
5. Konrad-Martin D, "Audiological monitoring of patients receiving ototoxic drugs", Perspect Hear Hear Disord Res Res Diagn, 9, pp.17~22 (2005)[DOI]
6. Coradini PP, "Ototoxicity from cisplatin therapy in childhood cancer", J Pediatr Hematol Oncol, 29, pp.355~360 (2007)[DOI]
7. McKeage MJ, "Comparative adverse effect profiles of platinum drugs", Drug Saf, 13, pp.228~244 (1995)[DOI]
8. Bisht M, "Ototoxicity: the hidden menace", Indian J Otolaryngol Head Neck Surg, 63, pp.255~259 (2011)[DOI]
9. Rybak LP, "Ototoxicity of loop diuretics", Otolaryngol Clin North Am, 26, pp.829~844 (1993)
10. Peters U, "Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin", Anticancer Drugs, 11, pp.639~643 (2000)[DOI]
11. Oldenburg J, "Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors", J Clin Oncol, 25, pp.708~714 (2007)[DOI]
12. Riedemann L, "Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin", Pharmacogenomics J, 8, pp.23~28 (2008)[DOI]
13. Ross CJ, "Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy", Nat Genet, 41, pp.1345~1349 (2009)[DOI]
14. Palodetto B, "Influence of glutathione s-transferase on the ototoxicity caused by aminoglycosides", Braz J Otorhinolaryngol, 76, pp.306~309 (2010)[DOI]
15. Rednam S, "Glutathione S-transferase P1 single nucleotide polymorphism predicts permanent ototoxicity in children with medulloblastoma", Pediatr Blood Cancer, 60, pp.593~598 (2013)[DOI]
16. Choeyprasert W, "Cisplatin-induced ototoxicity in pediatric solid tumors: the role of glutathione S-transferases and megalin genetic polymorphisms", J Pediatr Hematol Oncol, 35, pp.e138~e143 (2013)[DOI]
17. Pussegoda K, "Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children", Clin Pharmacol Ther, 94, pp.243~251 (2013)[DOI]
18. Yang JJ, "The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer", Clin Pharmacol Ther, 94, pp.252~259 (2013)[DOI]
19. Hagleitner MM, "Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts", PLoS One, 9, pp.e115869~ (2014)[DOI]
20. Qian Y, "Interaction of aminoglycosides with human mitochondrial 12S rRNA carrying the deafness-associated mutation", Antimicrob Agents Chemother, 53, pp.4612~4618 (2009)[DOI]
21. Xu H, "Common variants in ACYP2 influence susceptibility to cisplatininduced hearing loss", Nat Genet, 47, pp.263~266 (2015)[DOI]
22. Brown AL, "SOD2 genetic variant associated with treatment-related ototoxicity in cisplatin-treated pediatric medulloblastoma", Cancer Med, 4, pp.1679~1686 (2015)[DOI]
23. American Speech-Language-Hearing Association, "Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy", ASHA, 36(Suppl 12), pp.11~19 (1994)
24. Fausti SA, "High-frequency audiometric monitoring strategies for early detection of ototoxicity", Ear Hear, 15, pp.232~239 (1994)
25. "American Academy of Audiology position statement and clinical practice guidelines: ototoxicity monitoring"[URL]
26. Wilkinson JD, "Audit of hearing surveillance in UK paediatric cystic fibrosis units", J Cyst Fibros, 8(Suppl 2), pp.S107~ (2009)
27. Van Meter DJ, "A survey of oncedaily dosage tobramycin therapy in patients with cystic fibrosis", Pediatr Pulmonol, 44, pp.325~329 (2009)[DOI]
28. Al-Malky G, "An analysis of ototoxicity in children: audiological detection, clinical practice and genetic susceptibility", pp.2014
29. Knight KR, "Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions", J Clin Oncol, 25, pp.1190~1195 (2007)[DOI]
30. Reavis KM, "Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss", Ear Hear, 29, pp.875~893 (2008)[DOI]
31. Fausti SA, "High-frequency monitoring for early detection of cisplatin ototoxicity", Arch Otolaryngol Head Neck Surg, 119, pp.661~666 (1993)[DOI]
32. Abujamra AL, "The use of high-frequency audiometry increases the diagnosis of asymptomatic hearing loss in pediatric patients treated with cisplatin-based chemotherapy", Pediatr Blood Cancer, 60, pp.474~478 (2013)[DOI]
33. Geyer LB, "High frequency hearing thresholds and product distortion otoacoustic emissions in cystic fibrosis patients", Braz J Otorhinolaryngol, 81, pp.589~597 (2015)[DOI]
34. Fausti SA, "Early detection of ototoxicity using 1", 6th-octave steps, 2003, pp.14, 444~450
35. Fausti SA, "An individualized, sensitive frequency range for early detection of ototoxicity", Ear Hear, 20, pp.497~505 (1999)[DOI]
36. Vaughan NE, "An efficient test protocol for identification of a limited, sensitive frequency test range for early detection of ototoxicity", J Rehabil Res Dev, 39, pp.567~574 (2002)
37. Dille MF, "OtoID: new extended frequency, portable audiometer for ototoxicity monitoring", J Rehabil Res Dev, 50, pp.997~1006 (2013)[DOI]
38. Konrad-Martin D, "Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA)", J Rehabil Res Dev, 51, pp.81~100 (2014)[DOI]
39. Stavroulaki P, "Otoacoustic emissions for monitoring aminoglycoside-induced ototoxicity in children with cystic fibrosis", Arch Otolaryngol Head Neck Surg, 128, pp.150~155 (2002)[DOI]
40. Yilmaz S, "Detection of cisplatin-induced ototoxicity with transient evoked otoacoustic emission test before pure tone audiometer", Eur Arch Otorhinolaryngol, 267, pp.1041~1044 (2010)[DOI]
41. Md Daud MK, "Ototoxicity screening of patients treated with streptomycin using distortion product otoacoustic emissions", B-ENT, 10, pp.53~58 (2014)
42. 유광규, "Comparison of the Effectiveness of Monitoring Cisplatin-Induced Ototoxicity with Extended High-Frequency Pure-Tone Audiometry or Distortion-Product Otoacoustic Emission", Journal of Audiology & Otology, 18(2), pp.58~68 (2014), 대한청각학회
43. Dille MF, "Ototoxicity risk assessment combining distortion product otoacoustic emissions with a cisplatin dose model", J Acoust Soc Am, 128, pp.1163~1174 (2010)[DOI]
44. Reavis KM, "Distortion-product otoacoustic emission test performance for ototoxicity monitoring", Ear Hear, 32, pp.61~74 (2011)[DOI]
45. Crundwell G, "Ototoxicity (cochleotoxicity) classifications: a review", Int J Audiol, 55, pp.65~74 (2016)[DOI]
46. Chang KW, "Practical grading system for evaluating cisplatin ototoxicity in children", J Clin Oncol, 28, pp.1788~1795 (2010)[DOI]
47. Theunissen EA, "A new grading system for ototoxicity in adults", Ann Otol Rhinol Laryngol, 123, pp.711~718 (2014)[DOI]
48. Kushner BH, "Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma", Cancer, 107, pp.417~422 (2006)[DOI]
49. Yancey A, "Risk factors for cisplatin-associated ototoxicity in pediatric oncology patients", Pediatr Blood Cancer, 59, pp.144~148 (2012)[DOI]
50. Bertolini P, "Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss", J Pediatr Hematol Oncol, 26, pp.649~655 (2004)[DOI]
51. Al-Khatib T, "Cisplatinum ototoxicity in children, long-term follow up", Int J Pediatr Otorhinolaryngol, 74, pp.913~919 (2010)[DOI]
52. Kolinsky DC, "Late onset hearing loss: a significant complication of cancer survivors treated with cisplatin containing chemotherapy regimens", J Pediatr Hematol Oncol, 32, pp.119~123 (2010)[DOI]
53. Ahmed RM, "Gentamicin ototoxicity: a 23-year selected case series of 103 patients", Med J Aust, 196, pp.701~704 (2012)[DOI]
54. Rogers C, "Aminoglycoside-induced balance deficits: a review of vestibulotoxicity", S Afr Fam Pract, 53, pp.419~424 (2011)
55. Fouladi M, "Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma", J Clin Oncol, 26, pp.3749~3755 (2008)[DOI]
56. Riga MG, "Transtympanic injections of N-acetylcysteine for the prevention of cisplatin-induced ototoxicity: a feasible method with promising efficacy", Am J Clin Oncol, 36, pp.1~6 (2013)[DOI]
57. Gurney JG, "Evaluation of amifostine for protection against cisplatin- induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma", Neuro Oncol, 16, pp.848~855 (2014)[DOI]
58. Dias MA, "The chemopreventive effect of Ginkgo biloba extract 761 against cisplatin ototoxicity: a pilot study", Int Tinnitus J, 19, pp.12~19 (2015)
59. Feldman L, "Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine", Kidney Int, 72, pp.359~363 (2007)[DOI]
60. Doolittle ND, "Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors", Clin Cancer Res, 7, pp.493~500 (2001)
61. Marina N, "Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study", Cancer, 104, pp.841~847 (2005)[DOI]
62. Katzenstein HM, "Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group", Cancer, 115, pp.5828~5835 (2009)[DOI]
63. Marshak T, "Prevention of cisplatin-induced hearing loss by intratympanic dexamethasone: a Randomized Controlled Study", Otolaryngol Head Neck Surg, 150, pp.983~990 (2014)[DOI]
64. van As JW, "Medical interventions for the prevention of platinum-induced hearing loss in children with cancer", Cochrane Database Syst Rev (2014)
65. Landier W, "Ototoxicity and cancer therapy", Cancer, 122, pp.1647~1658 (2016)[DOI]
66. Lustig LR, "Cochlear gene therapy", Curr Opin Neurol, 25, pp.57~60 (2012)[DOI]
67. Santaolalla F, "Inner ear hair cell regeneration: a look from the past to the future", Neural Regen Res, 8, pp.2284~2289 (2013)

관련 논문AI추천